Skip to Content
Merck
CN

380R-2

Arginase-1 (EP261) Rabbit Monoclonal Primary Antibody

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

UNSPSC Code:
12352203

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

biological source

rabbit

Quality Level

100
500

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

EP261, monoclonal

description

For In Vitro Diagnostic Use in Select Regions

form

buffered aqueous solution

species reactivity

human

packaging

vial of 0.1 mL concentrate (380R-24)
vial of 0.1 mL concentrate Research Use Only (380R-24-RUO)
vial of 0.5 mL concentrate (380R-25)
vial of 1.0 mL concentrate (380R-26)
vial of 1.0 mL concentrate Research Use Only (380R-26-RUO)
vial of 1.0 mL pre-dilute Research Use Only (380R-27-RUO)
vial of 1.0 mL pre-dilute ready-to-use (380R-27)
vial of 7.0 mL pre-dilute ready-to-use (380R-28)
vial of 7.0 mL pre-dilute ready-to-use Research Use Only (380R-28-RUO)

manufacturer/tradename

Cell Marque®

technique(s)

immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200 (concentrated)

isotype

IgG

control

hepatocellular carcinoma, normal liver

shipped in

wet ice

storage temp.

2-8°C

visualization

cytoplasmic, nuclear

Gene Information

human ... ARG1(383)

Related Categories

General description

Arginase-1 is a key urea cycle metalloenzyme that has demonstrated expression in normal human liver with a high degree of specificity. Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver accounting for an estimated 70%-85% of total liver cancers worldwide. Diagnostic pitfalls exist in the morphologic distinction of HCC from other hepatocellular and non-hepatocellular lesions. In difficult or equivocal cases, the application of immunohistochemical (IHC) panels has been shown to aid in the distinction of benign and malignant liver lesions. In sections of normal liver, anti-arginase-1 produced strong, diffuse cytoplasmic reactivity in all hepatocytes throughout the lobule. In some cases, patchy nuclear reactivity is also evident in hepatocytes along with the cytoplasmic reactivity. Reactivity is not observed in bile duct epithelial cells, sinusoidal endothelial cells, Kupffer cells, or vascular endothelial cells. In sections of HCC, anti-arginase-1 produces cytoplasmic or cytoplasmic plus nuclear reactivity.

Physical form

Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide.

Preparation Note

Download the IFU specific to your product lot and format
Note: This requires a keycode which can be found on your packaging or product label.

Download the latest released IFU
Note: This IFU may not apply to your specific product lot.

Analysis Note


IVD
IVD
IVD
RUO

Other Notes

Arginase-1 Positive Control Slides, Product No. 380S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com

Legal Information

Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany

Not finding the right product?  

Try our Product Selector Tool.

Storage Class Code

12 - Non Combustible Liquids

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

监管及禁止进口产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000509478
0000509478
0000464891
0000464886
0000464887

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Nehal A Radwan et al.
Diagnostic pathology, 7, 149-149 (2012-11-01)
The ability to distinguish hepatocellular carcinoma (HCC) from metastatic carcinoma (MC) involving the liver and cholangiocarcinoma (CC) by immunohistochemistry has been limited by the lack of a reliable positive marker for hepatocellular differentiation. Arginase-1 is a marker for HCC recently
Benign and malignant tumors of the liver.
LINDA D. FERRELL
Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas, 2nd ed., Pages 1291-Pages 1325 (2009)
Thuy Nguyen et al.
Archives of pathology & laboratory medicine, 139(8), 1028-1034 (2015-08-01)
Several immunohistochemical markers are available to establish the diagnosis of hepatocellular carcinoma. Judicious selection is essential to achieve a reliable diagnosis in limited tissue provided by liver biopsy. To compare the efficacy of 5 hepatocellular markers for the diagnosis of
Ahmedin Jemal et al.
CA: a cancer journal for clinicians, 61(2), 69-90 (2011-02-08)
The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7
Aileen Wee
CytoJournal, 2, 7-7 (2005-06-09)
The role of fine needle aspiration biopsy (FNAB) in the evaluation of focal liver lesions has evolved. Guided FNAB is still useful to procure a tissue diagnosis if clinical, biochemical and radiologic findings are inconclusive. Major diagnostic issues include: (i)
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service